CML
BLOOD, CML
Blood samples were collected and used to characterize the PK profile of bosutinib in the population PK model. For the majority of the studies, extensive PK sampling was conducted; however, in the studies involving patients with CML, only sparse sampling was conducted. In BELA, eight blood samples per patient were collected: predose and 3 and 6 h postdose on Days 1 and 28, and predose on Days 56 and 84. In BFORE and B1871048, four blood samples per patient were collected: predose on Days 1, 28, 56, and 84.